2 completed, 1 recruiting, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow eflepedocokin alfa: new trials by email Literature Review of eflepedocokin alfa trials Research Report on eflepedocokin alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial IL-22, Prednisone, Acamprosate - Alcohol-associated Hepatitis | Phase 2 | Recruiting | Samer Gawrieh | 216 | 2026-01-27 | 2026-07-15 |
| Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia F-652, Placebo - COVID-19 Pneumonia | Phase 2 | Withdrawn | EVIVE Biotechnology | 2022-04-08 | 2023-10-02 | |
| Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19 F-652, Placebo - Covid19 | Phase 2 | Terminated | EVIVE Biotechnology | 1 | 2021-01-26 | 2023-12-21 |
| Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids - Acute Graft vs Host Disease | Phase 1 / Phase 2 | Completed | EVIVE Biotechnology | 30 | 2016-05-12 | 2021-07-22 |
| Use of F-652 in Patients With Alcoholic Hepatitis F-652 - Alcoholic Hepatitis | Phase 1 / Phase 2 | Completed | Mayo Clinic | 18 | 2016-02-01 | 2019-09-09 |
COVID-19 (1) · Hepatitis, Alcoholic (1)
EVIVE Biotechnology (3) · Mayo Clinic (1) · Samer Gawrieh (1)
United States (4)
Christine M Bojanowski, MD (1) · Doris Ponce, M.D. (1) · Vijay Shah, MD (1)
U24AA026969 (1)